A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

Summary

This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).

Timeline

Start

2022-08-31

Primary completion

2024-10-16

Completion

2025-04-09

Publications

• Van Den Blink B, Birring SS, Mogulkoc N, Atis SN, Gupta R, Guiot J, Hart SP, Carmona Porquera EM, Koeller HB, Arocho N, Petit CM, Denning J, Lin M, Baughman RP, Wijsenbeek-Lourens M, Reiss TF; RESOLVE-Lung investigators. Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study. Eur Respir J. 2026 Mar 12:2501874. doi: 10.1183/13993003.01874-2025. Online ahead of print.

Drugs

Indications